Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Class A common stock
-
Shares outstanding
-
4,195,190
-
Total 13F shares
-
3,172,878
-
Share change
-
-237,368
-
Total reported value
-
$3,077,787
-
Put/Call ratio
-
16%
-
Price per share
-
$0.97
-
Number of holders
-
26
-
Value change
-
-$231,380
-
Number of buys
-
9
-
Number of sells
-
9
Institutional Holders of Enlivex Therapeutics Ltd. - Class A common stock (ENLV) as of Q1 2025
As of 31 Mar 2025,
Enlivex Therapeutics Ltd. - Class A common stock (ENLV) was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,172,878 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, MILLENNIUM MANAGEMENT LLC, MORGAN STANLEY, RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC, CITADEL ADVISORS LLC, TWO SIGMA SECURITIES, LLC, SIGMA INVESTMENT COUNSELORS INC, Virtu Financial LLC, and NEUBERGER BERMAN GROUP LLC.
This page lists
26
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.